ASH 2020 | Moving the MPN field forward
Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the latest updates in the myeloproliferative neoplasms field, and what more needs to be done to get novel treatments developed and used in clinical practice. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Transcript (edited for clarity)
We are now, in over the last 10 to 20 minutes, we’re able to dissect to a small degree, what is happening in the field. And what’s happening in the field is such a novelty in the development of the therapeutic ability to identify new drugs, based on the biology, and develop them, hopefully very soon, for our patients in a clinic. How can we do that? We only can work together to achieve that goal...
We are now, in over the last 10 to 20 minutes, we’re able to dissect to a small degree, what is happening in the field. And what’s happening in the field is such a novelty in the development of the therapeutic ability to identify new drugs, based on the biology, and develop them, hopefully very soon, for our patients in a clinic. How can we do that? We only can work together to achieve that goal. Encouragement to seek clinical studies and encourage patient’s participation, sending patients to academic centers, if not locally available. For us all to get those drugs, that there are many of them as we said in Phase III studies. To get them proven effective and available to everybody for them to be commercially available, hopefully in a few years. So I would encourage everybody to learn about what’s happening with the new drugs, with the studies and participate and get us, develop those drugs together.
Read more...
Disclosures
Srdan Verstovsek, MD, PhD, has received research support for clinical studies from Incyte, Roche, NS, Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Abbvie, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Ital Pharma, Protagonist and Kartos.
